Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Roberto Salvia

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3514-8473; OpenAlex author ID A5071657406, A5109700580, A5159670714, A5160506212. Sources: OpenAlex.

Their work

Papers
142 (first author 3, last author 28)
Trials
0
Grants
0
Labs led
1
Collaborators
461
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 2 papers · 2014: none · 2015: 1 paper · 2016: 6 papers · 2017: 5 papers · 2018: 13 papers · 2019: 11 papers · 2020: 15 papers · 2021: 15 papers · 2022: 12 papers · 2023: 17 papers · 2024: 12 papers · 2025: 14 papers · 2026: 17 papers

Papers 50 of 142

  1. Presumed Intraductal Papillary Mucinous Neoplasms in Individuals at High Risk for Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2026.35610↗
  2. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  3. Discovering Hereditary Risk Through Surveillance: A Prospective Genetic Analysis of Individuals With Familial Pancreatic Cancer. Co-author DOI 10.1002/ueg2.70187↗
  4. Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis. Co-author DOI 10.1007/s00423-026-04291-0↗
  5. Early cellular plasticity promotes progression and dissemination in pancreatic adenocarcinoma. Co-author DOI 10.1007/s10555-026-10326-1↗
  6. Designing a national network of pancreas units: the Italian model for high-quality pancreatic cancer care. Co-author DOI 10.1007/s13304-026-02598-7↗
  7. Pancreatic cancer surgery in Italy: an updated snapshot from a national multicentre analysis of outcomes by hospital volume. Co-author DOI 10.1007/s13304-026-02813-5↗
  8. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from … Co-author DOI 10.1016/j.esmoop.2026.106964↗
  9. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  10. High fidelity of Claudin-18.2 expression in primary and matched metastatic (lymph nodes, peritoneum, and liver) pancreatic ductal adenocarcinoma: a foundation … Co-author DOI 10.1016/j.humpath.2025.106014↗
  11. Postpancreatectomy liver injury: A relevant entity in the modern era of pancreatic cancer surgery with hepatic vessel resection. A monocentric retrospective co… Co-author DOI 10.1016/j.surg.2026.110302↗
  12. Clonal evolutionary analysis reveals patterns of malignant transformation of Intraductal Papillary Mucinous Neoplasms of the pancreas. Co-author DOI 10.1038/s41467-026-69762-w↗
  13. Morphologic Characterization of Pancreatic Ductal Adenocarcinoma following Post-neoadjuvant Pancreatectomy and Clinical Value of Intratumor Heterogeneity. Co-author DOI 10.1097/sla.0000000000006565↗
  14. Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19218-8↗
  15. ASO Visual Abstract: Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19370-1↗
  16. Interpreting Circulating Bile Acid Profiles in Pancreatic Cancer: The Role of Cholestasis and Its Management. Co-author DOI 10.3390/cancers18152481↗
  17. Correction: Danese et al. Interpreting Circulating Bile Acid Profiles in Pancreatic Cancer: The Role of Cholestasis and Its Management. Cancers 2026, 18, 2481. Co-author DOI 10.3390/cancers18193144↗
  18. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  19. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  20. Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characte… Co-author DOI 10.1002/path.6437↗
  21. Pancreatic cancer and long survivors: a survey of Italian society of oncological surgery (SICO). Co-author DOI 10.1007/s13304-024-02039-3↗
  22. Local ablation disrupts immune evasion in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.217327↗
  23. Impact of exercise in patients with pancreatic cancer across different treatment phases: A systematic review. Co-author DOI 10.1016/j.critrevonc.2025.104961↗
  24. Chemotherapy enhances HMGA1 secretion through the mutant p53-CK2 axis in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1038/s41419-025-08082-1↗
  25. MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. Co-author DOI 10.1038/s41586-025-08721-9↗
  26. Resection to Exploration Ratios and Associated Outcomes in Patients with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/sla.0000000000006197↗
  27. Reappraising the Role of Intraoperative Neck Margin Revision in Postneoadjuvant Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Multi-institution… Last author DOI 10.1097/sla.0000000000006322↗
  28. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  29. Carbohydrate Antigen 19-9 Delta Function for Survival Prediction in Borderline Pancreatic Cancer. A PANC-PALS Consortium International Multicenter Derivation a… Co-author DOI 10.1097/sla.0000000000006735↗
  30. Expert Judgment Supporting a Bayesian Network to Model the Survival of Pancreatic Cancer Patients. Co-author DOI 10.3390/cancers17020301↗
  31. Assessment of Psychological Burden in Individuals with Hereditary Risk of Pancreatic Cancer Under Surveillance: Evaluation of Distress 3 Years After Enrollment. Last author DOI 10.3390/cancers17183014↗
  32. Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2024.2485↗
  33. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Co-author DOI 10.1007/s13304-024-01860-0↗
  34. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial. Co-author DOI 10.1016/j.ejca.2023.113430↗
  35. The value of splenectomy during left-sided pancreatectomy for pancreatic ductal adenocarcinoma: predefined subanalysis in the DIPLOMA randomized trial. Co-author DOI 10.1093/bjs/znae236↗
  36. Surveillance of Individuals at High Risk of Developing Pancreatic Cancer: A Prevalence Meta-analysis to Estimate the Rate of Low-yield Surgery. Co-author DOI 10.1097/sla.0000000000006094↗
  37. Cure Probabilities After Resection of Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Analysis of 2554 Patients. Co-author DOI 10.1097/sla.0000000000006166↗
  38. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  39. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  40. Adjuvant Therapy After Upfront Resection of Resectable Pancreatic Cancer: Patterns of Omission and Use-A Prospective Real-Life Study. Last author DOI 10.1245/s10434-024-14951-4↗
  41. ASO Author Reflections: Adjuvant Therapy for Resectable Pancreatic Cancer in the Real World-Not as Common as One Might Think. Last author DOI 10.1245/s10434-024-15014-4↗
  42. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. Co-author DOI 10.14309/ajg.0000000000002546↗
  43. The Difficulty of Detecting Occult Metastases in Patients with Potentially Resectable Pancreatic Cancer: Development and External Validation of a Preoperative … Co-author DOI 10.3390/jcm13061679↗
  44. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  45. Immunonutrition and prehabilitation in pancreatic cancer surgery: A new concept in the era of ERAS® and neoadjuvant treatment. Co-author DOI 10.1016/j.ejso.2022.12.006↗
  46. A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic te… Co-author DOI 10.1016/j.esmoop.2023.100881↗
  47. Contact system and intrinsic pathway activation in patients with advanced pancreatic cancer: a prospective cohort study. Co-author DOI 10.1016/j.jtha.2023.06.009↗
  48. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  49. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells. Co-author DOI 10.1016/j.modpat.2023.100251↗
  50. A dynamic analysis of empirical survival outcomes after pancreatectomy for pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.surg.2022.11.015↗

Closest collaborators

The 25 strongest of 461 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giuseppe Malleo · 73 shared papers, 2011–2026 · strength 10.04
  2. Salvatore Paiella · 57 shared papers, 2015–2026 · strength 7.39
  3. Claudio Bassi · 71 shared papers, 2011–2025 · strength 7.22
  4. Gabriella Lionetto · 24 shared papers, 2021–2026 · strength 4.51
  5. Aldo Scarpa · 32 shared papers, 2017–2026 · strength 4.17
  6. Claudio Luchini · 26 shared papers, 2019–2026 · strength 3.94
  7. Fabio Casciani · 19 shared papers, 2018–2026 · strength 3.49
  8. Massimo Falconi · 21 shared papers, 2013–2026 · strength 3.07
  9. Matteo De Pastena · 21 shared papers, 2018–2026 · strength 3.03
  10. Laura Maggino · 26 shared papers, 2017–2026 · strength 2.99
  11. Michèle Milella · 22 shared papers, 2019–2026 · strength 2.73
  12. Alessandro Esposito · 16 shared papers, 2018–2026 · strength 2.52
  13. Giovanni Marchegiani · 24 shared papers, 2011–2026 · strength 2.49
  14. Antonio Pea · 16 shared papers, 2019–2026 · strength 2.42
  15. Erica Secchettin · 17 shared papers, 2018–2026 · strength 2.23
  16. Giovanni Butturini · 20 shared papers, 2011–2026 · strength 2.04
  17. Rita Teresa Lawlor · 16 shared papers, 2017–2026 · strength 2.03
  18. Mirko D’Onofrio · 20 shared papers, 2015–2025 · strength 1.88
  19. Stefano Crippa · 10 shared papers, 2013–2026 · strength 1.65
  20. Isabella M. Frigerio · 17 shared papers, 2012–2026 · strength 1.55
  21. Giulio Belfiori · 8 shared papers, 2023–2026 · strength 1.54
  22. Paola Mattiolo · 9 shared papers, 2020–2026 · strength 1.48
  23. Alessandro Zerbi · 11 shared papers, 2019–2026 · strength 1.40
  24. Riccardo Casadei · 10 shared papers, 2021–2025 · strength 1.33
  25. Marc G. Besselink · 12 shared papers, 2018–2026 · strength 1.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.